Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 2, Février 2006
Page(s) 188 - 191
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006222188
Publié en ligne 15 février 2006
  1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129 : 92–6.
  2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 : 1600–7.
  3. Lyell A. Toxic epidermal necrolysis : an eruption resembling scalding of the skin. Br J Dermatol 1956; 68 : 355–61.
  4. Merot Y, Saurat JH. Clues to pathogenesis of toxic epidermal necrolysis. Int J Dermatol 1985; 24 : 165–8.
  5. Miyauchi H, Hosokawa H, Akaeda T, et al. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol 1991; 127 : 851–5.
  6. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells : an immunopathologic study of five cases. Arch Dermatol 1992; 128 : 50–3
  7. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement. Arch Dermatol1993; 129 : 466–8.
  8. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134 : 710–4.
  9. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130 : 605–8.
  10. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282 : 490–3.
  11. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand. Am J Pathol 2003; 162 : 1515–20.
  12. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor alpha, interleukin-6 and their receptors in toxic epidermal necrolysis : a comparison with second-degree burns. Int J Mol Med 1998; 1 : 459–62.
  13. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352 : 1586–9.
  14. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Dermatol Venereol 1999; 79 : 288–90.
  15. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol2004; 140 : 890–2.
  16. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139 : 33–6.
  17. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis : does immunoglobulin make a difference ? J Burn Care Rehabil 2004; 25 : 81–8.
  18. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25 : 246–55.
  19. Berthou C, Michel L, Soulie A, et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997; 159 : 5293–300.
  20. Paquet P, Pierard GE. Keratinocyte injury in toxic epidermal necrolysis : simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002; 10 : 145–7.
  21. Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004; 16 : 732–7.
  22. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119 : 225–30.
  23. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118 : 728–33.
  24. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis : effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114 : 1209–15.
  25. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123 : 850–5.
  26. Shresta S, Pham CTN, Thomas DA, et al. How do cytotoxic lymphocytes kill their targets ? Curr Opin Immunol 1998; 10 : 581–7.
  27. Azukizawa H, Kosaka H, Sano S, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 2003; 33 : 1879–88.
  28. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428 : 86.
  29. Hung SL, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102 : 4134–9.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.